- Previous Close
0.0008 - Open
0.0009 - Bid 0.0009 x --
- Ask 0.0010 x --
- Day's Range
0.0009 - 0.0011 - 52 Week Range
0.0004 - 0.0024 - Volume
25,180,597 - Avg. Volume
18,838,202 - Market Cap (intraday)
804,638 - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.
www.gcanrx.com1
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GCAN
View More
Performance Overview: GCAN
Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GCAN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GCAN
View MoreValuation Measures
Market Cap
804.64k
Enterprise Value
1.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-84.91%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-179.04k
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
57.37k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-42.35k